JPMorgan raised the firm’s price target on Privia Health (PRVA) to $35 from $33 and keeps an Overweight rating on the shares. The firm views the company’s Q4 report as solid. It increased estimates post the print.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRVA: